Related Experiment Video

Updated: Dec 15, 2025

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.1K

Unnecessary hesitancy on human vaccine tests

Nir Eyal1

  • 1Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ 08901, USA, and Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ 08854, USA. nir.eyal@rutgers.edu.

Science (New York, N.Y.)
|July 11, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.1K
Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
08:58

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Published on: April 30, 2019

9.3K

Related Experiment Videos

Last Updated: Dec 15, 2025

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.1K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.1K
Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
08:58

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Published on: April 30, 2019

9.3K

Related Concept Videos

Vaccinations01:51

Vaccinations

50.7K
Overview
50.7K
Cross-reactivity00:42

Cross-reactivity

32.6K
Overview
32.6K
Cancer Vaccines01:30

Cancer Vaccines

861
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
861
Hypothesis: Accept or Fail to Reject?01:17

Hypothesis: Accept or Fail to Reject?

29.2K
The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
29.2K

Articles linked to this work by shared authors, journal, and citation graph.

The United States Withdrawal From the World Health Organization: Implications and Challenges.

International journal of health policy and management·2025

U.S. Physicians' Views on E-Cigarette Risks and Benefits to Adults Who Smoke Versus Young People Who Do Not Smoke.

AJPM focus·2025

Managing infectious aerosols to counter engineered pandemics: Current recommendations and future research.

Risk analysis : an official publication of the Society for Risk Analysis·2025

Assessing the risks of current COVID-19 challenge trials systematically.

Vaccine·2025

Willingness to trade-off years of life for an HIV cure - an experimental exploration of affective forecasting.

AIDS research and therapy·2024

Dual-use research and research using enhanced pathogens in high-income countries: whose business?

mSphere·2024

Short-term emicizumab in patients with acquired hemophilia A.

Haematologica·2026

An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

Journal of medical economics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us